Modification of vitreal matrix metalloproteinase activity
AssigneeWilliam Beaumont Hospital
InventorsMichael T. Trese, George A. Williams, Michael Hartzer, Wendelin Dailey
Life of this patent
Estimating the term…
Loading patent…
AssigneeWilliam Beaumont Hospital
InventorsMichael T. Trese, George A. Williams, Michael Hartzer, Wendelin Dailey
Estimating the term…
Methods of modifying total MMP activity levels in the vitreous of an eye are provided. In a preferred embodiment, the method results in reduced MMP activity and comprises introducing plasmin into the vitreous of the eye. Enzyme assisted vitrectomy procedures are also provided, and comprise introducing plasmin into the vitreous in an amount sufficient to induce posterior detachment of the vitreous, mechanically detaching the vitreous from the eye, introducing a replacement fluid into the eye, and introducing plasmin into the eye in an amount sufficient to decrease the total MMP activity in vitreous. Considering the purported roles of MMPs in a variety of vitreal pathologies, the present invention provides methods of inhibiting the progression of various disease conditions, including prolifertaive diabetic retinopathy.
A method of performing a vitrectomy on an eye and providing post-procedure treatment to said eye, the method comprising:
A method of performing a vitrectomy on an eye and providing post-procedure treatment to the eye, the method comprising:
Dependencies are inferred from the claim text.